Impact of blood processing variations on natural killer cell frequency, activation, chemokine receptor expression and function.
Understanding the role of natural killer (NK) cells in human disease pathogenesis is crucial and necessitates study of patient samples directly ex vivo. Manipulation of whole blood by density gradient centrifugation or delays in sample processing due to shipping, however, may lead to artifactual changes in immune response measures. Here, we assessed the impact of density gradient centrifugation and delayed processing of both whole blood and peripheral blood mononuclear cells (PBMC) at multiple timepoints (2-24 h) on flow cytometric measures of NK cell frequency, activation status, chemokine receptor expression, and effector functions. We found that density gradient centrifugation activated the NK cells and modified the chemokine receptor expression. Delays in processing beyond 8h activated NK cells in PBMC but not in whole blood. Likewise, processing delays decreased chemokine receptor (CCR4 and CCR7) expression in both PBMC and whole blood. Finally, delays in processing PBMC were associated with a decreased ability of NK cells to degranulate (as measured by CD107a expression) or secrete cytokines (IFN-γ and TNF-α). In summary, our findings suggest that density gradient centrifugation and delayed processing of PBMC can alter measures of clinically relevant NK cell characteristics including effector functions; and therefore should be taken into account in designing clinical research studies.
HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa.
Vivek
V
Naranbhai
Pat
P
Bartman
Dudu
D
Ndlovu
Pamela
P
Ramkalawon
Thumbi
T
Ndung'u
Douglas
D
Wilson
Marcus
M
Altfeld
William H
WH
Carr
D000328:Adult; D001800:Blood Specimen Collection / Q000379:methods*; D015550:Cell Degranulation / Q000276:immunology; D002469:Cell Separation / Q000379:methods*; D002499:Centrifugation, Density Gradient; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007694:Killer Cells, Natural / Q000166:cytology* / Q000276:immunology* / Q000502:physiology; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology; D008213:Lymphocyte Activation; D018962:Phlebotomy; D019707:Receptors, Chemokine / Q000378:metabolism; D013997:Time Factors; D055815:Young Adult
D019707:Receptors, Chemokine
Clin Vaccine Immunol. 2009 Aug;16(8):1176-86
19515870
J Immunol. 2010 Sep 1;185(5):2808-18
20679529
Cytokine Growth Factor Rev. 2005 Dec;16(6):637-58
15998596
J Immunol Methods. 1993 Sep 15;164(2):263-73
8370932
Eur J Immunol. 2004 Aug;34(8):2313-21
15259029
Clin Diagn Lab Immunol. 1995 May;2(3):337-42
7545079
J Immunol Methods. 2008 Dec 31;339(2):132-40
18848564
J Immunol Methods. 2009 Feb 28;341(1-2):68-75
19041316
J Immunol Methods. 1984 Oct 12;73(1):29-40
6333461
Eur J Immunol. 2003 Sep;33(9):2410-8
12938217
J Immunol. 2009 May 15;182(10):5914-8
19414742
Clin Immunol. 2006 Jan;118(1):1-10
16337194
Clin Lab Haematol. 2002 Dec;24(6):353-9
12452816
J Immunol Methods. 2003 Aug;279(1-2):199-207
12969561
AIDS Res Hum Retroviruses. 2007 Jan;23(1):86-92
17263637
PLoS Pathog. 2008 Jul 11;4(7):e1000101
18617991
Eur J Immunol. 1993 Jul;23(7):1643-8
8100776
Blood. 2007 May 15;109(10):4296-305
17272507
J Immunol. 2006 Dec 1;177(11):7833-40
17114454
J Immunol Methods. 2004 Nov;294(1-2):15-22
15604012
J Immunol Methods. 2007 Apr 30;322(1-2):57-69
17382342
Clin Diagn Lab Immunol. 2000 Sep;7(5):759-63
10973450
Immunology. 2007 Jun;121(2):258-65
17346281
AIDS Res Hum Retroviruses. 2010 Apr;26(4):459-69
20380481
J Immunol Methods. 1987 Apr 2;98(1):53-6
2951443